PartnershipAug 4, 2026, 08:52 AM
Evolus Expands Symatese Partnership to Canada, Australia, NZ
AI Summary
Evolus, Inc. announced an amendment to its existing license agreement with Symatese Aesthetics S.A.S., expanding its exclusive commercialization rights for Estyme® branded injectable hyaluronic acid gels to Canada, Australia, and New Zealand. This strategic move aims to establish a consistent multi-product commercial platform across Evolus' global business, complementing its existing neurotoxin franchise. Evolus Europe will make an upfront payment of €920,000 and up to €1.38 million upon regulatory approvals, with commercialization anticipated in 2028.
Key Highlights
- Evolus expanded its license agreement with Symatese to include Canada, Australia, and New Zealand.
- Evolus Europe gains exclusive rights to commercialize Estyme® branded injectable hyaluronic acid gels in these territories.
- Evolus will pay €920,000 in upfront signing payments.
- Up to an additional €1.38 million is payable upon receipt of certain regulatory approvals.
- The initial term for each new territory is 15 years from the first regulatory approval.
- Symatese will handle development and regulatory activities for the new territories.
- Commercialization of Estyme® in these markets is expected in 2028.
- The total addressable market for neurotoxins and dermal fillers in these regions is approximately $500 million annually.
Price Impact
More from EOLS